CompletedNot Applicable

Natural Disease Progression in Participants With Choroideremia

United States1,178 participantsStarted 2020-08-26

Plain-language summary

The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants and to match CHM participants in the Intelligent Research in Sight (IRIS®) Registry to Biogen's investigator sponsored trial (IST) study population using propensity score matching.

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ICD-9: 363.55
✓. ICD-10: H31.2
✓. SNOMED-CT: 75241009
✓. ICD-9: 363.55
✓. ICD-10: H31.21
✓. SNOMED-CT: 75241009

What they're measuring

Percentage of Participants with Progression of Best Corrected Visual Acuity (BCVA) in Relation to Age

Timeframe: Up to 6 years

Percentage of Participants with Progression of BCVA Over Time After the Baseline BCVA

Timeframe: Up to 6 years

Trial details

NCT IDNCT04795206

SponsorBiogen

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-05-07

View on ClinicalTrials.gov More Choroideremia trials